
Results
7
Companies which are more than 50% undervalued based on analyst price target.
7 companies
Caliway Biopharmaceuticals
Market Cap: NT$163.4b
Engages in the development of drugs for aesthetic medicine and chronic inflammation.
6919
NT$105.00
7D
-2.3%
1Y
-16.7%
Bora Pharmaceuticals
Market Cap: NT$51.1b
Engages in contract development, manufacture, and sale of pharmaceuticals in Europe, the United States, Taiwan, and internationally.
6472
NT$401.00
7D
-2.9%
1Y
-41.0%
Lotus Pharmaceutical
Market Cap: NT$50.1b
Engages in the research and development, manufacture, and sale of generic pharmaceutical products in Taiwan, South Korea, the United States, and internationally.
1795
NT$190.50
7D
-4.5%
1Y
-11.0%
Oneness Biotech
Market Cap: NT$22.9b
Engages in the research, development, and sale of new drugs, pharmaceuticals, and health products in Taiwan.
4743
NT$47.80
7D
-2.4%
1Y
-23.6%
TaiMed Biologics
Market Cap: NT$16.0b
A biotechnology company, develops, manufactures, and commercializes drugs for the treatment and prevention of infectious diseases.
4147
NT$58.50
7D
-8.9%
1Y
-28.3%
Medigen Vaccine Biologics
Market Cap: NT$15.3b
A biotechnology drug company, engages in the research, development, and wholesale of vaccines and biopharmaceuticals, and medical devices in Taiwan.
6547
NT$46.65
7D
3.6%
1Y
14.6%
Foresee Pharmaceuticals
Market Cap: NT$12.9b
Operates as biopharmaceutical company in the United States, China, and Europe.
6576
NT$82.20
7D
1.6%
1Y
14.0%